Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children

Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic. ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising. The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017. Few clinical data have been published so far concerning the French population. The investigators would like to build a database so that the investigators can publish our results and share our experience.

NCT Number	NCT04252989
Lead Sponsor	Centre Hospitalier Universitaire de Saint Etienne
Conditions	Myopia, Children
Enrollment	50 participants
Start Date	2019-12-18
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-03-18